Sugi Predict

Sugi Predict / Compounds / SCHEMBL1154972

SCHEMBL1154972

SCHEMBL1154972

COC(=O)C1CC(OS(C)(=O)=O)CN1C(=O)OC(C)(C)C

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 4/20 0.48
▸ ANPEP P15144 4/20 0.48
▸ NR1H2 P55055 2/20 0.44
▸ NR1H3 Q13133 1/20 0.44
▸ PTPN1 P18031 1/20 0.42
▸ P2RX3 P56373 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38
▸ UCHL1 P09936 1/20 0.36
▸ MCL1 Q07820 5/20 0.35
▸ CHRM2 P08172 1/20 0.35
▸ CHRM1 P11229 1/20 0.35
▸ CHRM3 P20309 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ HSD11B1 P28845 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5058842 1.00 MMP2 (0.48) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL489252 1.00 MMP2 (0.48) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL699280 1.00 MMP2 (0.48) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL5691732 1.00 MMP2 (0.48) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL7805563 1.00 MMP2 (0.48) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL2252585 1.00 MMP2 (0.48) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL8607697 0.92 MMP2 (0.40) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL8609251 0.92 MMP2 (0.40) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL25436769 0.88 NR1H2 (0.43) MMP2ANPEPNR1H2NR1H3PTPN1
SCHEMBL19898506 0.88 NR1H2 (0.43) MMP2ANPEPNR1H2NR1H3PTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015003723-A1 SUBSTITUTED 4-PROLINE DERIVATIVES AS IGLUR ANTAGONISTS Københavns Universitet (DK) 2015-01-15 — — WO claimed
US-10961246-B2 18F-labelled folates as PET radiotracers Merck & Cie (CH) 2021-03-30 — — US disclosed
US-20180072734-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS Merck & Cie (CH) 2018-03-15 — — US disclosed
EP-3131892-A2 POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS Cocrystal Pharma, Inc. (US) 2017-02-22 — — EP disclosed
US-9499519-B2 Fused pyrimidine compounds and use thereof MEDIVATION TECHNOLOGIES, INC. (US) 2016-11-22 — — US disclosed
US-20160068513-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF MEDIVATION TECHNOLOGIES, INC. (US) 2016-03-10 — — US disclosed
EP-2776409-B1 MACROCYCLIC COMPOUNDS FOR INHIBITION OF INHIBITORS OF APOPTOSIS ENSEMBLE THERAPEUTICS CORP (US) 2016-02-03 — — EP disclosed
WO-2015160907-A2 POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS COCRYSTAL PHARMA, INC. (US) 2015-10-22 — — WO disclosed
EP-2346870-B1 18F-LABELLED FOLATES AS PET RADIOTRACERS Merck & Cie (CH) 2015-08-05 — — EP disclosed
WO-2015003723-A1 SUBSTITUTED 4-PROLINE DERIVATIVES AS IGLUR ANTAGONISTS Københavns Universitet (DK) 2015-01-15 — — WO disclosed
EP-1338595-B1 Xanthine derivatives as DPP-IV inhibitors EISAI CO LTD (JP) 2006-05-03 — — EP disclosed
US-20050239770-A1 N-heterocyclic inhibitors of TNF-alpha expression MORIARTY KEVIN J 2005-10-27 — — US disclosed
US-6906067-B2 N-heterocyclic inhibitors of TNF-α expression BRISTOL-MYERS SQUIBB COMPANY (US) 2005-06-14 — — US disclosed
US-20050004114-A1 Heterocycle substituted carboxylic acids INSTITUTE FOR DIABETES DISCOVERY, L.L.C. 2005-01-06 — — US disclosed
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor EISAI CO., LTD. (JP) 2004-04-29 — — US disclosed
EP-1338595-A2 Xanthine derivatives as DPP-IV inhibitors Eisai Co., Ltd. (JP) 2003-08-27 — — EP disclosed
US-20020137747-A1 N- heterocyclic inhibitors of TNF-alpha expression PHARMACEOPEIA, INC. 2002-09-26 — — US disclosed
EP-1242385-A1 CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS PHARMACOPEIA, INC. (US) 2002-09-25 — — EP disclosed
US-20020065270-A1 N-heterocyclic inhibitors of TNF-alpha expression PHARMACOPEIA, INC. 2002-05-30 — — US disclosed
WO-2001047897-A1 CYTOKINE, ESPECIALLY TNF-ALPHA, INHIBITORS PHARMACOPEIA, INC. (US) 2001-07-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239770-A1 N-heterocyclic inhibitors of TNF-alpha expression TNF, RELA, NFKBIA MMP2 1074/4885ANPEP 1212/4885NR1H2 1322/4885
US-20040082570-A1 Xanthine derivative and DPPIV inhibitor DPP4, DPP9, DPP7 MMP2 372/4885ANPEP 282/4885NR1H2 952/4885
US-20160068513-A1 FUSED PYRIMIDINE COMPOUNDS AND USE THEREOF IGF1R, FGFR3, FGFR1 MMP2 3587/4885ANPEP 3578/4885NR1H2 1691/4885
US-20180072734-A1 18F-LABELLED FOLATES AS PET RADIOTRACERS FOLR1, FOLR2, SLC19A1 MMP2 4297/4885ANPEP 1260/4885NR1H2 3931/4885
US-20020137747-A1 N- heterocyclic inhibitors of TNF-alpha expression TNF, NFKBIA, RELA MMP2 1120/4885ANPEP 1460/4885NR1H2 1378/4885
US-20020065270-A1 N-heterocyclic inhibitors of TNF-alpha expression TNF, NFKBIA, RELA MMP2 1120/4885ANPEP 1460/4885NR1H2 1378/4885
US-10961246-B2 18F-labelled folates as PET radiotracers FOLR1, FOLR2, SLC19A1 MMP2 4297/4885ANPEP 1260/4885NR1H2 3931/4885
US-20050004114-A1 Heterocycle substituted carboxylic acids PTPRC, PTPRS, PTPRJ MMP2 3533/4885ANPEP 1508/4885NR1H2 3691/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.